

Complementary stereoselective conjugate addition reactions on indolo[2,3-*a*]quinolizine templates

Steven M. Allin,^{a,*} Jagjit S. Khera,^a Christopher I. Thomas,^a Jason Witherington,^b Kevin Doyle,^c Mark R. J. Elsgood^a and Mark Edgar^a

^aDepartment of Chemistry, Loughborough University, Loughborough, Leicestershire LE11 3TU, UK

^bDepartment of Medicinal Chemistry, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research Limited, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK

^cOSI Pharmaceuticals, Watlington Road, Oxford OX4 6LT, UK

Received 21 November 2005; revised 6 January 2006; accepted 16 January 2006


Available online 7 February 2006

Abstract—We report a new and highly stereoselective approach for the construction of a range of functionalized indolo[2,3-*a*]quinolizine targets from a readily available, nonracemic chiral template. The methods developed allow us to predetermine relative product stereochemistries by judicious choice of substrate sub-structure.

© 2006 Elsevier Ltd. All rights reserved.

The indolo[2,3-*a*]quinolizine ring system **1** is of considerable interest and significance since this heterocyclic template is found within a plethora of indole alkaloids, including geissoschizine **2**,¹ geissoschizol **3**² and hirsutine **4**.³ The presence of the lactam carbonyl in templates such as **1** allows for possible further functionalization en route to the natural product targets. Recent approaches to the construction of this heterocyclic target system by other groups have included the diastereoselective vinylogous Mannich reaction,⁴ Bischler–Napieralski reaction,⁵ Fischer indole synthesis⁶ and an asymmetric Pictet–Spengler reaction.⁷

We have developed a new approach for the stereoselective synthesis of the indolo[2,3-*a*]quinolizine ring system that involves the cyclization of a pendent indole substituent onto an *N*-acyliminium intermediate as the key ring-forming step.⁸ We have recently applied our methodology in natural product synthesis, and have reported the asymmetric preparation of some simple indole alkaloids, including deplancheine.⁹ In order to access more advanced targets such as **2–4**, and their synthetic analogues, one would require suitable and flexible routes for the introduction of additional functionality to the indolo[2,3-*a*]quinolizine template, ideally with control over relative and absolute stereochemistry. One approach currently under study in our laboratory is to



introduce appropriate functionality through conjugate addition to the lactam ring. Scheme 1 highlights the preparation of a model substrate for this investigation from indolizino[2,3-*a*]quinolizidine derivative **5**, obtained as a single diastereoisomer as previously reported.⁸

* Corresponding author. E-mail: S.M.Allin@lboro.ac.uk

With α,β -unsaturated amide **7** in hand, we turned our attention to the proposed functionalization of the β -position through the conjugate addition chemistry shown in Scheme 2.


The products of conjugate addition were isolated in varying yields: **8** (52%), **9** (20%) and **10** (65%); we were pleased to observe the formation, in each case, of the desired product as a single diastereoisomer by examination of the crude reaction mixtures by 250 MHz ^1H NMR spectroscopy. The relative stereochemistry of each product was confirmed by NOE studies. Protons at positions 2 and 12b have *trans* relative stereochemistry, as seen in the natural product hirsutine, **4**.³

All nucleophiles gave the same sense of stereochemical induction with template **7**, and although this appears to result from the nucleophile approaching the face of the conjugated amide that carries the large benzyloxy-methyl-substituent, the representations shown in Scheme 2 can be misleading, since the conformation of molecules such as **7** is bowl-like, and the nucleophiles


are approaching from the outer (perhaps less hindered) face of the bowl; that is, from the same face as the H-atom at the proximate ring junction.

An intriguing and potentially very useful effect on the sense of nucleophilic addition was observed on further modification of the template sub-structure. Unsaturated substrate **16** was prepared as a single enantiomer following the method outlined in Scheme 3. Removal of the hydroxymethyl substituent in this way would be a natural progression en route to final targets such as **2–4** noted at the outset of this letter, and this protocol is now a standard transformation in our laboratory.⁹


With the structures of potential targets **2–4** in mind we subjected compound **16** to the addition of 2 equiv of lithiated methyl 1,3-dithiolane-2-carboxylate and were pleased to observe the exclusive formation of the addition product **17** as a single diastereoisomer in 47% yield (Fig. 1). Analysis of compound **17** by X-ray crystallography¹⁰ revealed that the addition had occurred on the opposite face to that observed in the studies outlined



Scheme 1. Reagents and conditions: (i) NaH (2 equiv), BnBr (2.2 equiv), DMF, rt, 1 h (90%); (ii) LDA, PhSeBr, THF, $-78\text{ }^\circ\text{C}$ to rt, 24 h, then (iii) NaIO₄, NaHCO₃, MeOH, H₂O, rt, 18 h (85% for two steps).



Scheme 2.



Scheme 3. Reagents and conditions: (i) IBX, DMSO, rt, 24 h (70%); (ii) Et₃N, (Boc)₂O, DMAP, THF, rt, 4 h (98%); (iii) NaClO₂, NaH₂PO₄, 1-methyl-1-cyclohexene, CH₃CN, *t*-BuOH, H₂O, $0\text{ }^\circ\text{C}$ to rt, 18 h (83%); (iv) (PhSe)₂, PBu₃, CH₂Cl₂, $0\text{ }^\circ\text{C}$ to rt, 18 h (83%); (v) *n*-Bu₃SnH, AIBN, toluene, $80\text{ }^\circ\text{C}$, 2 h (73%); (vi) LDA, PhSeBr, THF, $-78\text{ }^\circ\text{C}$ to rt, 24 h, then NaIO₄, NaHCO₃, MeOH, H₂O, rt, 18 h (85% for two steps).





Figure 1.



Scheme 4.

above, with the protons at positions 2 and 12b now having *cis* relative stereochemistry, as in the natural products geissoschizine **2**¹ and geissoschizol **3**.²

A remarkable manipulation in the sense of stereochemical induction can be achieved with template **18**, that lacks any *N*-protection at the indole nitrogen (obtained through formic acid-mediated deprotection of **16** [neat, rt, 22 h, 71% yield]). In this case, addition of the lithiated dithiolane nucleophile (2 equiv) led to selective formation of product **19** in which the protons at positions 2 and 12b were found to be of *trans* relative stereochemistry, as seen previously with template **7**, and as required in the natural product hirsutine, **4**.³

The full potential of our approach for the efficient stereoselective total synthesis of indole natural products can be demonstrated with the addition of an excess of the lithiated dithiolane nucleophile (4 equiv) to substrate **18**. We reasoned that the dithiolane moiety could serve a dual role: as both a nucleophile and subsequently, in the same pot, as an electrophile for derivatization of an intermediate lactam enolate. This domino process would provide a highly economic route to access advanced heterocyclic templates. We were pleased to isolate product **20** in 64% yield and as a single diastereoisomer (Scheme 4). Product **20** has the correct relative stereochemistry at all three chiral centres

required for a future synthesis of hirsutine, **4**, as confirmed by X-ray crystallography (Scheme 4).¹¹

In conclusion, we have found that the relative stereochemistry of the products of conjugate addition to indolo[2,3-*a*]quinolizine molecules can be influenced through careful selection of the template structure, allowing complementary approaches to diastereoisomeric addition products.¹² With either the hydroxymethyl auxiliary group present, or judicious choice of indole *N*-protection, nucleophilic addition occurs to give *cis* relative stereochemistry between the newly added substituent and the proton at ring junction 12b. An alternative manipulation of the template structure can lead to the introduction of *trans* relative stereochemistry between these two groupings. In addition, we have discovered that the use of a dithiolane reagent in a domino-type process can lead to highly efficient and stereoselective functionalization of our template. Current work is focused on extending the methodology described in this paper to other, more complex indole alkaloid targets. Our progress will be reported in due course.

Acknowledgements

One of the authors (C.I.T.) thanks Loughborough University and OSI Pharmaceuticals, for a joint studentship

and J.S.K. thanks Loughborough University and GSK Pharmaceuticals, for a joint studentship.

References and notes

- Martin, S. F.; Chen, K. X.; Eary, C. T. *Org. Lett.* **1999**, *1*, 79–81.
- Wenkert, E.; Guo, M.; Pestchanker, M. J.; Shi, Y.-J.; Vankar, Y. D. *J. Org. Chem.* **1989**, *54*, 1166–1174.
- Takayama, H.; Iimura, Y.; Kitajima, M.; Aimi, N.; Konno, K.; Inoue, H.; Fujiwara, M.; Mizuta, T.; Yokota, T.; Shigeta, S.; Tokuhisa, K.; Hanasaki, H.; Katsuura, K. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 3145–3148; Lounasmaa, M.; Miettinen, J.; Hanhinen, P.; Jokela, R. *Tetrahedron Lett.* **1997**, *38*, 1455–1458; Tietze, L. F.; Zhou, Y. *Angew. Chem., Int. Ed.* **1999**, *38*, 2045–2047.
- Deiters, A.; Chen, K.; Eary, C. T.; Martin, S. F. *J. Am. Chem. Soc.* **2003**, *125*, 4541–4550.
- Deiters, A.; Martin, S. F. *Org. Lett.* **2002**, *4*, 3243–3245.
- Fornicola, R. S.; Subburaj, K.; Montgomery, J. *Org. Lett.* **2002**, *4*, 615–617.
- Liu, X.; Wang, T.; Xu, Q.; Ma, C.; Cook, J. M. *Tetrahedron Lett.* **2000**, *41*, 6299–6303.
- (a) Allin, S. M.; Thomas, C. I.; Allard, J. E.; Duncton, M.; Elsegood, M. R. J.; Edgar, M. *Tetrahedron Lett.* **2003**, *44*, 2335–2337; (b) Allin, S. M.; Vaidya, D. G.; James, S. L.; Allard, J. E.; Smith, T. A. D.; McKee, V.; Martin, W. P. *Tetrahedron Lett.* **2002**, *43*, 3661–3663; (c) Allin, S. M.; James, S. L.; Martin, W. P.; Smith, T. A. D.; Elsegood, M. R. J. *J. Chem. Soc., Perkin Trans. 1* **2001**, 3029–3036; (d) Allin, S. M.; James, S. L.; Martin, W. P.; Smith, T. A. D. *Tetrahedron Lett.* **2001**, *41*, 3943–3946; (e) Allin, S. M.; Northfield, C. J.; Page, M. I.; Slawin, A. M. Z. *Tetrahedron Lett.* **1998**, *39*, 4905–4908.
- Allin, S. M.; Thomas, C. I.; Allard, J. E.; Doyle, K.; Elsegood, M. R. J. *Tetrahedron Lett.* **2004**, *45*, 7103–7105; Allin, S. M.; Thomas, C. I.; Doyle, K.; Elsegood, M. R. J. *J. Org. Chem.* **2005**, *70*, 357–359; Allin, S. M.; Thomas, C. I.; Allard, J. E.; Doyle, K.; Elsegood, M. R. J. *Eur. J. Org. Chem.* **2005**, 4179–4186.
- Crystallography for **17**: C₂₅H₃₀N₂O₅S₂, *M* = 502.63, monoclinic, *P*2₁, *a* = 10.5505(7), *b* = 9.3807(6), *c* = 12.4921(8) Å, β = 100.281(2)°, *V* = 1216.51(14) Å³, *Z* = 2, 10,789 data measured, *R*_{int} = 0.0192, *wR*₂ = 0.0905 for all 5594 unique data, *R*₁ = 0.0379 for 5007 data with $F^2 \geq 2\sigma(F^2)$. Absolute structure parameter = −0.03(6)—thus reliably determined. CCDC 286786 contains supplementary crystallographic data in cif format. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK. Fax: +44 1223 336033, e-mail: deposit@ccdc.cam.ac.uk).
- Crystallography for **20**: C₂₄H₂₆N₂O₄S₄, *M* = 534.71, orthorhombic, *P*2₁2₁2₁, *a* = 7.6895(7), *b* = 17.2611(16), *c* = 18.2799(17) Å, *V* = 2426.3(4) Å³, *Z* = 4, 21508 data measured, *R*_{int} = 0.0208, *wR*₂ = 0.0705 for all 5875 unique data, *R*₁ = 0.0287 for 5417 data with $F^2 \geq 2\sigma(F^2)$. Absolute structure parameter = −0.03(5)—thus reliably determined. H-bonded chains along *a* via N(12)–H(12)···O(1'), CCDC 286787.
- Data for selected compounds: Compound **7**: δ_{H} (400 MHz; CDCl₃) 2.21–2.30 (1H, m), 2.52–2.59 (1H, m), 3.02 (1H, ddd, *J* 16, 8, 4), 3.15 (1H, d, *J* 16), 3.30–3.38 (2H, m), 4.45 (2H, s), 4.59–4.63 (1H, m, C=CCH), 5.23 (2H, dd, *J* 36, 16), 5.42–5.46 (1H, m), 6.06 (1H, dd, *J* 8, 4), 6.49–6.50 (1H, m), 6.83–6.85 (2H, m), 7.14–7.23 (11H, m), 7.60–7.62 (1H, m); δ_{C} (100 MHz, CDCl₃) 21.9 (CH₂), 32.0 (CH₂), 47.3 (CH), 48.3 (CH₂), 49.8 (CH), 68.0 (CH₂), 72.5 (CH₂), 107.6 (C), 109.8 (CH), 118.7 (CH), 119.9 (CH), 122.3 (CH), 125.6 (2 × CH), 125.9 (CH), 127.0 (C), 127.3 (2 × CH), 127.3 (CH), 127.5 (CH), 128.2 (2 × CH), 128.9 (2 × CH), 132.6 (C), 137.0 (C), 138.1 (C), 138.2 (C), 138.2 (CH), 164.9 (NC=O); MS (EI) *m/z* 448 [M⁺, 100.0%] (Found: M⁺, 448.21406. C₃₀H₂₈N₂O₂ requires 448.21507). Compound **16**: δ_{H} (400 MHz, CDCl₃) 1.69 (9H, s), 2.13–2.22 (1H, m), 2.72–2.80 (2H, m), 2.82–2.92 (1H, m), 3.03 (1H, ddd, *J* 17.2, 6.6, 3.8), 5.02 (1H, ddd, *J* 12.5, 4.8, 1.4), 5.24–5.30 (1H, m), 6.09 (1H, dd, *J* 9.7, 1.5), 6.67–6.71 (1H, m), 7.26–7.35 (2H, m), 7.47–7.49 (1H, m), 8.08 (1H, d, *J* 8.0); δ_{C} (100 MHz, CDCl₃) 21.5 (CH₂), 28.2 (3 × CH₃), 31.6 (CH₂), 37.6 (CH₂), 53.3 (CH), 84.5 (C), 115.8 (CH), 118.0 (C), 118.4 (CH), 123.1 (CH), 124.7 (CH), 125.4 (CH), 128.5 (C), 134.1 (C), 136.6 (C), 139.2 (CH), 150.0 (NC(O)O^tBu), 164.8 (NC=O); MS (EI) *m/z* 338 [M⁺, 24.4%] (Found: M⁺, 338.16318. C₂₀H₂₂N₂O₃ requires 338.16384). Compound **17**: δ_{H} (400 MHz, CDCl₃) 1.38–1.47 (1H, m), 1.70 (9H, s), 2.53 (1H, dd, *J* 17.4, 11.7), 2.69–2.80 (2H, m), 2.81–2.85 (2H, m), 2.87–2.89 (1H, m), 2.95–3.03 (1H, m), 3.28–3.33 (2H, m), 3.35–3.39 (2H, m), 3.81 (3H, s), 5.10–5.17 (2H, m), 7.23–7.33 (2H, m), 7.43–7.45 (1H, m), 8.02–8.04 (1H, m); δ_{C} (100 MHz, CDCl₃) 21.7 (CH₂), 28.1 (3 × CH₃), 33.8 (CH₂), 35.7 (CH₂), 38.4 (CH), 39.0 (CH₂), 40.1 (CH₂), 40.3 (CH₂), 53.5 (CH₃), 55.4 (CH), 74.1 (C), 84.5 (C), 115.5 (CH), 118.4 (CH), 118.7 (C), 123.1 (CH), 124.8 (CH), 128.5 (C), 134.7 (C), 136.8 (C), 150.3 (NC(O)O^tBu), 168.7 (C=O), 171.9 (NC=O); MS (EI) *m/z* 502 [M⁺, 3.5%] (Found: M⁺, 502.15989. C₂₅H₃₀N₂O₅S₂ requires 502.15962). Compound **20**: δ_{H} (400 MHz, CDCl₃) 2.29–2.33 (1H, m), 2.79–2.89 (2H, m), 2.79–2.89 (1H, m), 3.15–3.27 (4H, m), 3.35–3.37 (2H, m), 3.45–3.48 (2H, m), 3.49–3.52 (1H, m), 3.88 (3H, s), 4.33–4.36 (1H, m), 4.98 (1H, t, *J* 8.4), 5.11–5.13 (1H, m), 5.92 (1H, s), 7.10–7.20 (2H, m), 7.32–7.34 (1H, m), 7.49 (1H, d, *J* 7.6), 7.87 (1H, br s); δ_{C} (100 MHz, CDCl₃) 20.9 (CH₂), 29.3 (CH₂), 30.9 (CH), 38.2 (CH₂), 38.3 (CH₂), 39.1 (CH₂), 40.4 (CH₂), 41.3 (CH₂), 51.0 (CH), 53.8 (CH₃), 54.8 (CH), 56.3 (CH), 73.9 (C), 109.7 (C) 110.9 (CH), 118.4 (CH), 119.9 (CH), 122.2 (CH), 126.8 (C), 131.9 (C), 136.3 (C), 164.8 (C=O), 171.8 (NC=O), 198.1 (C=O); MS (FAB) *m/z* 535 [MH⁺, 5.2%] (Found: MH⁺, 535.08460. C₂₄H₂₆N₂O₄S₄ requires 535.08537).